TScan Therapeutics is a clinical-stage biotechnology company that built its credibility in the blood-cancer space, and that credibility is now the only thing holding the story together. The company paused enrollment in the Phase 3 trial of its lead product, TSC-101, a candidate for relapse prevention after transplant. It cut roughly three-quarters of its workforce and let its Amgen collaboration lapse, all to redirect what little cash it has toward an in vivo solid-tumor program it has never dosed in a patient. The strategic pivot is defensible, but it converts a data-rich late-stage asset into a first-in-mechanism bet at a company that no longer has the bench to develop it.
The equity is a survival play with an embedded partnership option, and the market has already decided the price. TScan trades near the bottom of its range, below its book value, with a going-concern qualification on the books and a Nasdaq bid-price deficiency carrying a cure date in early 2027. What the current share price is paying for is not a program but the odds that the strongest data in the company's history, the complete donor chimerism result in Cohort C of the ALLOHA trial, matures into a transaction before the cash is exhausted. The in vivo program is the new priority and the old story; the heme program is the old priority and the new option. The investment case turns entirely on which of those two assets a buyer shows up for, and whether it shows up in time.